PRGN-3006 is under clinical development by Precigen and currently in Phase I for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Refractory Acute Myeloid Leukemia have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PRGN-3006’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

PRGN-3006 overview

PRGN-3006 is under development for the treatment of cancer including relapsed/refractory acute myeloid leukemia, chronic myelomonocytic leukemia (CMML), myelodysplastic syndrome. It is composed of cells expressing chimeric antigen receptors (CAR) and a cytokine. It acts by targeting CD33, mbIL15 and a kill switch for better precision and control. The drug candidate is administered through intravenous route. It is developed based on sleeping beauty CAR+ T cells non-viral system.

Precigen overview

Precigen is a clinical-stage biotechnology company that discovers, develops and commercializes next-generation gene and cell therapies to target diseases in immuno-oncology, autoimmune disorders and infections. The company’s clinical pipeline includes AG019, PRGN-3005, PRGN-3006, PRGN-3007, PRGN-2009 and PRGN-2012 for the indications of type 1 diabetes, ovarian cancer, acute myeloid leukemia and myelodysplastic syndromes, hematological and solid tumors, recurrent respiratory papillomatosis. Precigen preclinical pipeline includes PRGN-5001, PRGN-2010, PRGN-2011, PRGN-2013 and AG017, among others for solid tumors and celiac disease. The company utilizes therapeutic platforms including UltraCAR-T, AdenoVerse therapies, ActoBiotics, multifunctional therapeutics, UltraVector, AdenoVerse, AttSite, UltraPorator and RheoSwitch, among others. The company operates in the US and Belgium. Precigen is headquartered in Germantown, Maryland, the US.

For a complete picture of PRGN-3006’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.